Improving Biologic Drugs via Total Chemical Synthesis
Abstract
Most biologic therapeutics are large, complex molecules or heterogeneous mixtures of molecules that are manufactured in a living system (e.g., microorganism, plant cell, or animal cell) through recombinant DNA technology. Biologics are now being used to treat a wide range of diseases, including cancer, autoimmune disorders, and diabetes. It is estimated that half of the top 100 best-selling medications will soon be biologics, with Roche's anticancer biologic Avastin and AbbVie's anti-inflammatory antibody Humira rivaling the success of Pfizer's small-molecule drug Lipitor (1). Biologics differ fundamentally from small-molecule drugs in terms of purity, composition, and production. Small-molecule drugs typically have homogeneous, well-defined structures that have been finely tuned with atomic-level precision via chemical synthesis. On page 1357 of this issue, Wang et al. (2) bridge the gap between biologics and small-molecule drugs by accomplishing the total chemical synthesis of the biologic erythropoietin (EPO) in a single, pure form.
Additional Information
© 2013 American Association for the Advancement of Science.Additional details
- Eprint ID
- 43182
- DOI
- 10.1126/science.1247615
- Resolver ID
- CaltechAUTHORS:20140102-144409776
- Created
-
2014-01-04Created from EPrint's datestamp field
- Updated
-
2021-11-10Created from EPrint's last_modified field